Fecal Microbiota Capsules for Primary Sclerosing Cholangitis
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current treatments for primary sclerosing cholangitis are inadequate, with ursodeoxycholic acid associated with adverse effects and limited efficacy, and there is a need for more effective and easily administered therapies.
Innovation Solution
Administration of a pharmaceutically active dose of live non-pathogenic fecal bacteria, either alone or in combination with other medications, to treat primary sclerosing cholangitis, with dosing regimens ranging from once daily to twice weekly for several weeks or months, aiming to achieve remission, cure, or resolution of symptoms.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If ursodeoxycholic acid is used to treat primary sclerosing cholangitis, then the disease can be treated, but adverse effects occur and efficacy is limited
Solution Approach 1:
The patent introduces fecal microbiota as an intermediary therapeutic agent that mediates the treatment of primary sclerosing cholangitis through restoration of gut microbiome balance, offering an alternative pathway that avoids the adverse effects of ursodeoxycholic acid while maintaining therapeutic efficacy
2Ease of operation
If conventional treatments are used for primary sclerosing cholangitis, then treatment can be provided, but more effective and easily administered therapies are needed
Solution Approach 1:
The patent employs oral capsules containing fecal microbiota that patients can self-administer at home, eliminating the need for complex hospital-based procedures like colonoscopic infusions or enemas, thereby greatly improving ease of operation while maintaining or enhancing treatment effectiveness through standardized dosing
Data Source
AI summary
The present disclosure is in the field of pharmaceutical compositions suitable for the treatment of diseases in mammals. The disclosure provides novel compositions comprising non-pathogenic fecal microbes for treating primary sclerosing cholangitis and related diseases. The disclosure also provides methods for treating a subject with the compositions disclosed herein.